RU2758378C1 - Немолизумаб в лечении атопического дерматита с экскориацией от умеренной до тяжелой - Google Patents

Немолизумаб в лечении атопического дерматита с экскориацией от умеренной до тяжелой Download PDF

Info

Publication number
RU2758378C1
RU2758378C1 RU2020129578A RU2020129578A RU2758378C1 RU 2758378 C1 RU2758378 C1 RU 2758378C1 RU 2020129578 A RU2020129578 A RU 2020129578A RU 2020129578 A RU2020129578 A RU 2020129578A RU 2758378 C1 RU2758378 C1 RU 2758378C1
Authority
RU
Russia
Prior art keywords
nemolizumab
excoriation
weeks
skin
patients
Prior art date
Application number
RU2020129578A
Other languages
English (en)
Russian (ru)
Inventor
Набил КЕРРУШ
Кейко ХИРОКАВА
Риосуке МИХАРА
Original Assignee
Галдерма Холдинг СА
Чугаи Сейяку Кабусики Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Галдерма Холдинг СА, Чугаи Сейяку Кабусики Кайся filed Critical Галдерма Холдинг СА
Application granted granted Critical
Publication of RU2758378C1 publication Critical patent/RU2758378C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2020129578A 2018-02-09 2019-02-08 Немолизумаб в лечении атопического дерматита с экскориацией от умеренной до тяжелой RU2758378C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862628714P 2018-02-09 2018-02-09
US62/628,714 2018-02-09
PCT/IB2019/051051 WO2019155427A1 (en) 2018-02-09 2019-02-08 Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Publications (1)

Publication Number Publication Date
RU2758378C1 true RU2758378C1 (ru) 2021-10-28

Family

ID=65729402

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020129578A RU2758378C1 (ru) 2018-02-09 2019-02-08 Немолизумаб в лечении атопического дерматита с экскориацией от умеренной до тяжелой

Country Status (23)

Country Link
US (2) US12435147B2 (https=)
EP (2) EP4644424A3 (https=)
JP (3) JP7777921B2 (https=)
CN (1) CN112040976A (https=)
AU (2) AU2019219608B2 (https=)
BR (1) BR112020016144A2 (https=)
CA (1) CA3090062A1 (https=)
CL (1) CL2020002050A1 (https=)
DK (1) DK3749353T3 (https=)
ES (1) ES3049513T3 (https=)
FI (1) FI3749353T3 (https=)
HR (1) HRP20251101T1 (https=)
IL (1) IL276524A (https=)
LT (1) LT3749353T (https=)
MX (1) MX2020008193A (https=)
PH (1) PH12020551185A1 (https=)
PL (1) PL3749353T3 (https=)
PT (1) PT3749353T (https=)
RU (1) RU2758378C1 (https=)
SG (1) SG11202007558YA (https=)
SI (1) SI3749353T1 (https=)
TW (1) TWI856006B (https=)
WO (1) WO2019155427A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025095100A1 (ja) * 2023-11-02 2025-05-08 マルホ株式会社 医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2980992A1 (en) * 2015-04-14 2016-10-20 Akihisa Kaneko Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
WO2017093857A1 (en) * 2015-11-30 2017-06-08 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
EP1858924A1 (en) * 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2980992A1 (en) * 2015-04-14 2016-10-20 Akihisa Kaneko Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
WO2017093857A1 (en) * 2015-11-30 2017-06-08 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Carmela Avena-Woods, Overview of atopic dermatitis, Am J Manag Care. 2017 Jun; 23(8 Suppl):S115-S123, найдено онлайн, найдено в Интернете: https://www.ajmc.com/view/overview-of-atopic-dermatitis-article. *
O. NEMOTO ET AL, "The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-co", BRITISH JOURNAL OF DERMATOLOGY, 174 (2), 19 December 2015 (2015-12-19), page 296-304, найдено онлайн, найдено в Интернете: https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.14207. *
Ruzicka, T., et al., Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. New England Journal of Medicine, 2017, 376(9), 826-835, найдено онлайн, найдено в Интернете: https://pubmed.ncbi.nlm.nih.gov/28249150/. *
Ruzicka, T., et al., Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. New England Journal of Medicine, 2017, 376(9), 826-835, найдено онлайн, найдено в Интернете: https://pubmed.ncbi.nlm.nih.gov/28249150/. O. NEMOTO ET AL, "The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-co", BRITISH JOURNAL OF DERMATOLOGY, 174 (2), 19 December 2015 (2015-12-19), page 296-304, найдено онлайн, найдено в Интернете: https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.14207. SOHEI OYAMA et al, "Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody", EXPERIMENTAL DERMATOLOGY, 27(1), 10 April 2017 (2017-04-10), page 14-21, title, abstract; p. 15, найдено онлайн, найдено в Интернете: https://pubmed.nc *
SOHEI OYAMA et al, "Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody", EXPERIMENTAL DERMATOLOGY, 27(1), 10 April 2017 (2017-04-10), page 14-21, title, abstract; p. 15, найдено онлайн, найдено в Интернете: https://pubmed.ncbi.nlm.nih.gov/27714851/. *

Also Published As

Publication number Publication date
MX2020008193A (es) 2020-11-24
LT3749353T (lt) 2025-09-25
CL2020002050A1 (es) 2020-12-11
IL276524A (en) 2020-09-30
HRP20251101T1 (hr) 2025-11-21
JP2021512917A (ja) 2021-05-20
TW201941800A (zh) 2019-11-01
BR112020016144A2 (pt) 2020-12-15
WO2019155427A1 (en) 2019-08-15
PH12020551185A1 (en) 2021-05-17
SG11202007558YA (en) 2020-09-29
EP3749353A1 (en) 2020-12-16
AU2019219608A1 (en) 2020-08-27
EP4644424A2 (en) 2025-11-05
TW202448919A (zh) 2024-12-16
PL3749353T3 (pl) 2025-12-08
ES3049513T3 (en) 2025-12-17
US20200385476A1 (en) 2020-12-10
US12435147B2 (en) 2025-10-07
AU2026200182A1 (en) 2026-01-29
JP2023182632A (ja) 2023-12-26
AU2019219608B2 (en) 2025-10-16
CN112040976A (zh) 2020-12-04
DK3749353T3 (da) 2025-09-01
CA3090062A1 (en) 2019-08-15
SI3749353T1 (sl) 2025-10-30
JP7777921B2 (ja) 2025-12-01
JP2025176134A (ja) 2025-12-03
TWI856006B (zh) 2024-09-21
EP3749353B1 (en) 2025-07-30
US20260008859A1 (en) 2026-01-08
PT3749353T (pt) 2025-10-14
EP4644424A3 (en) 2026-01-14
FI3749353T3 (fi) 2025-09-10

Similar Documents

Publication Publication Date Title
US20200031937A1 (en) Vedolizumab for the treatment of fistulizing crohn's disease
US11034761B2 (en) Compositions and methods for reducing adiposity by inhibiting FSH/FSHR
JP7671822B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
JP2024531205A (ja) アトピー性皮膚炎の治療のためのｉｌ－１３抗体
CN119095617A (zh) 用于治疗患有头皮斑块型银屑病的受试者的方法
US20260008859A1 (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
CA3228708A1 (en) Treatment of atopic dermatitis
TWI870471B (zh) 全身性硬化症治療用醫藥組合物
HK40130865A (en) Treatment of atopic dermatitis with moderate to severe excoriation
HK40042731A (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
HK40042731B (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
US20260078181A1 (en) Trem-2 agonists for the treatment of marfan syndrome
RU2822134C2 (ru) Лечение поражений кожи и зуда у пациентов с узловатой почесухой
US20220403018A1 (en) Methods of treating lichen planus using interleukin (il-17) antagonists
CN120826237A (zh) Il-13抗体用于治疗特应性皮炎
KR20260057215A (ko) 결절성 양진 환자에서 피부 병변 및 소양증의 치료